<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01889290</url>
  </required_header>
  <id_info>
    <org_study_id>RELZH12</org_study_id>
    <nct_id>NCT01889290</nct_id>
  </id_info>
  <brief_title>Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients</brief_title>
  <acronym>RELZH12</acronym>
  <official_title>Pharmacokinetics of Once Daily Subcutaneous Methylnaltrexone in Neurointensive Care Patients With High Dose Sufentanil Analgosedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Assessment of pharmacokinetic parameters of once daily subcutaneously administered&#xD;
           methylnaltrexone in 10 evaluable neurointensive care patients.&#xD;
&#xD;
        -  Quantification of methylnaltrexone passage through the blood-brain-barrier in critically&#xD;
           ill patients with severe cerebral affections.&#xD;
&#xD;
        -  Observation of laxation response after methylnaltrexone application and relation to&#xD;
           plasma concentrations of methylnaltrexone.&#xD;
&#xD;
        -  Assessing the safety of once daily administered methylnaltrexone in neurointensive care&#xD;
           patients.&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After administration of methylnaltrexone s.c. multiple peripheral blood samples and&#xD;
      additionally two liquor samples are drawn during a dose interval on day 1, 3, and 5 of drug&#xD;
      administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of methylnaltrexone (Cmax, tmax, area under the curve, total clearance, halflife, accumulation ratio, renal clearance)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Opioid Use, Unspecified With Other Opioid-induced Disorder</condition>
  <arm_group>
    <arm_group_label>Methylnaltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacokinetics of methylnaltrexone administered once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone</intervention_name>
    <description>Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl</description>
    <arm_group_label>Methylnaltrexone</arm_group_label>
    <other_name>Relistor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  hospitalisation in the neurointensive care unit&#xD;
&#xD;
          -  deep sedation with sufentanil doses of = 40 mcg/h&#xD;
&#xD;
          -  male or female aged 18 years or older&#xD;
&#xD;
          -  females: negative pregnancy test&#xD;
&#xD;
          -  Ventricular drainage as part of needed therapeutic measures&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of hypersensitivity to methylnaltrexone (RelistorÂ®)&#xD;
&#xD;
          -  confirmed or suspected obstructive ileus or factors possibly leading to intestinal&#xD;
             obstruction (e.g. an intestinal tumor)&#xD;
&#xD;
          -  increased risk for patients with localized or diffused reduction in structural&#xD;
             integrity of the gastrointestinal tract (e.g. peptic ulcer, acute diverticulitis)&#xD;
&#xD;
          -  severe hepatic insufficiency (Child-Pugh Class C)&#xD;
&#xD;
          -  renal impairment (glomerular filtration rate &lt; 90 ml/min) with or without renal&#xD;
             replacement therapy&#xD;
&#xD;
          -  severe diarrhea despite high opioid dosing&#xD;
&#xD;
          -  participation in another study with an investigational drug within the 30 days&#xD;
             preceding and during the present study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natascia Corti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Pharmacology and Toxicology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurointensive Care Unit</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>methylnaltrexone</keyword>
  <keyword>opioid-antagonist</keyword>
  <keyword>Obstipation</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylnaltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

